21 Jun 2024
The US Food and Drug Adminisatration has announced it has expanded the approval of Sarepta Therapeutics’ gene therapy, known as Elevidys, for the treatment of ambulatory and non-ambulatory people with Duchenne aged 4 and over. In June last year we shared that...
1 Nov 2023
Pharmaceutical company Sarepta has announced results of Part 1 of its Phase 3 Embark gene therapy trial for Duchenne. The trial did not meet its primary endpoint: showing a difference in a change on the North Star Ambulatory Assessment (NSAA) total score – which...